

Special Issue

Nanoparticulate Delivery Systems for Antiviral Drugs

Message from the Guest Editors

Antiviral drugs are extensively used to combat viral infections, mainly through targeting the common stages of the viral life cycle, including entry, biosynthesis, assembly, and release. However, the delivery of antiviral drugs, especially small molecules and antibodies, is largely confronted with some challenges, notably in stability, off-target accumulation and intracellular delivery requirements. Nanoparticulate delivery systems have been developed to overcome these limitations. Various nanostructures, including extracellular vesicles, liposomes, dendrimers, polymers, silicon or carbon materials, nanogels, and magnetic nanoparticles, have been applied as carriers in antiviral drug delivery. Compared with traditional treatments, these nanoscale carriers largely strengthen the long-term circulation, local penetration, microenvironment targeting, and controlled release of antiviral drugs. Furthermore, the size, shape, charge, and surface modification of nanoparticles determine the fate of antiviral drugs in body. This Special Issue of *Pharmaceuticals* aims to assemble the recent developments in the field of nanoparticulate delivery systems for antiviral drugs.

Guest Editors

Dr. Yan Pang

School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Dr. Lu Wang

Institute of Molecular Medicine, Shanghai Jiao Tong University, Shanghai, China

Deadline for manuscript submissions

closed (31 October 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145572

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)